In mice vaccinated subcutaneously with different doses of virulent W.E.E. virus or with formolized vaccine, neutralizing and complement-fixing antibodies paralleled resistance to some extent yet appeared in groups in which resistance remained undetectable, persisted at a similar maximum level in spite of different titers of resistance, and after resistance had become negligible. In mice vaccinated subcutaneously with different doses of virulent St. Louis encephalitis virus or with formolized vaccine, neutralizing and complement-fixing antibodies bore little relation to resistance. Neutralizing antibodies appeared only in the group showing resistance but not until resistance was diminishing. Complement-fixing antibodies developed equally well in groups with or without resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2135422 | PMC |
| http://dx.doi.org/10.1084/jem.78.6.447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms.
Vaccines (Basel)
December 2024
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
: Generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen-Spike (S)-glycoprotein-after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)).
View Article and Find Full Text PDFAntibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System.
J Infect Dis
May 2023
VBU Discovery Research, Takeda Vaccines, Inc, Cambridge, Massachusetts, USA.
Background: Antibody-driven complement system (CS) activation has been associated with protection against symptomatic dengue virus (DENV) infection. Aggregation, opsonization, lysis, and phagocytosis are mechanisms triggered by antibody-antigen immunocomplexes following fixation of the component 1q (C1q) and activation of the classical pathway. As a result, DENV neutralization and clearance are facilitated, whereas antibody-dependent enhancement of infection is inhibited.
View Article and Find Full Text PDFBeyond Binding: The Outcomes of Antibody-Dependent Complement Activation in Human Malaria.
Front Immunol
November 2021
Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
Antibody immunity against malaria is effective but non-sterile. In addition to antibody-mediated inhibition, neutralisation or opsonisation of malaria parasites, antibody-mediated complement activation is also important in defense against infection. Antibodies form immune complexes with parasite-derived antigens that can activate the classical complement pathway.
View Article and Find Full Text PDFVaccination of foals with a modified live, equid herpesvirus-1 gM deletion mutant (RacHΔgM) confers partial protection against infection.
Vaccine
January 2020
Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Robert von Ostertag-Str. 7-13, 14163 Berlin, Germany.
Equid herpesvirus-1 (EHV-1) causes respiratory and neurological disease and late gestation abortion in pregnant mares. Current vaccines contain either inactivated or live EHV-1, but fail to provide complete clinical or virological protection, namely prevention of nasopharyngeal shedding and cell-associated viraemia. Thus, the development of novel products, such as modified live virus (MLV) vaccines which stimulate virus-specific, humoral and cell mediated immune responses more effectively remains a priority.
View Article and Find Full Text PDFHepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Vaccine
March 2019
Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, Victoria 3000, Australia; Royal Melbourne Institute of Technology (RMIT) University, School of Science, Melbourne, Victoria 3001, Australia. Electronic address:
The repetitive structure of compact virus-like particles (VLPs) provides high density displays of antigenic sequences, which trigger key parts of the immune system. The hepatitis B virus (HBV) and human papilloma virus (HPV) vaccines exploit the assembly competence of structural proteins, which are the effective immunogenic components of the prophylactic HBV and HPV vaccines, respectively. To optimize vaccine designs and to promote immune responses against protective epitopes, the "Asp-Ala-Asp-Pro" (NANP)-repeat from the Plasmodium falciparum circumsporozoite protein (CSP) was expressed within the exposed, main antigenic site of the small HBV envelope protein (HBsAgS); this differs from the RTS,S vaccine, in which CSP epitopes are fused to the N-terminus of HBsAgS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!